IRIS
RUSCITTI, PIERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.555
AS - Asia 5.704
EU - Europa 5.256
SA - Sud America 768
AF - Africa 105
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 11
Totale 22.412
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.375
SG - Singapore 2.671
RU - Federazione Russa 1.459
IE - Irlanda 1.395
CN - Cina 1.075
BR - Brasile 665
HK - Hong Kong 628
VN - Vietnam 550
IT - Italia 484
DE - Germania 395
SE - Svezia 359
TR - Turchia 328
GB - Regno Unito 230
UA - Ucraina 228
FR - Francia 198
FI - Finlandia 160
NL - Olanda 114
IN - India 105
CA - Canada 97
BD - Bangladesh 86
JP - Giappone 66
MX - Messico 53
BE - Belgio 46
ZA - Sudafrica 43
AR - Argentina 41
PL - Polonia 34
ES - Italia 30
LT - Lituania 27
CZ - Repubblica Ceca 23
ID - Indonesia 23
IQ - Iraq 22
EC - Ecuador 18
KR - Corea 16
PK - Pakistan 16
AT - Austria 14
VE - Venezuela 14
JO - Giordania 11
MA - Marocco 11
SA - Arabia Saudita 11
GR - Grecia 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
EU - Europa 9
AZ - Azerbaigian 8
CH - Svizzera 8
CO - Colombia 8
DZ - Algeria 8
EG - Egitto 8
IL - Israele 8
PH - Filippine 8
RO - Romania 8
UZ - Uzbekistan 8
KE - Kenya 7
LB - Libano 7
PY - Paraguay 7
AL - Albania 6
AU - Australia 6
JM - Giamaica 6
KZ - Kazakistan 6
NP - Nepal 6
KW - Kuwait 5
MY - Malesia 5
BO - Bolivia 4
DO - Repubblica Dominicana 4
LU - Lussemburgo 4
MK - Macedonia 4
NI - Nicaragua 4
PE - Perù 4
SN - Senegal 4
UY - Uruguay 4
CI - Costa d'Avorio 3
CL - Cile 3
DK - Danimarca 3
HN - Honduras 3
HR - Croazia 3
MM - Myanmar 3
NZ - Nuova Zelanda 3
OM - Oman 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
BG - Bulgaria 2
CR - Costa Rica 2
CW - ???statistics.table.value.countryCode.CW??? 2
EE - Estonia 2
ET - Etiopia 2
GH - Ghana 2
GT - Guatemala 2
HU - Ungheria 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MO - Macao, regione amministrativa speciale della Cina 2
PA - Panama 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
AO - Angola 1
BB - Barbados 1
Totale 22.392
Salva come PNG Salva come JPEG
Città #
Dublin 1.392
Singapore 1.357
San Jose 1.242
Dallas 1.210
Chandler 1.137
Jacksonville 942
Ashburn 789
Hong Kong 620
Santa Clara 563
Boardman 388
Council Bluffs 376
The Dalles 317
New York 316
Moscow 262
Izmir 208
Beijing 205
Los Angeles 180
Ho Chi Minh City 169
Lawrence 161
Princeton 161
Ann Arbor 151
Nanjing 125
Hanoi 124
Wilmington 123
Lauterbourg 100
L'aquila 99
Amsterdam 96
San Mateo 83
Hefei 79
Munich 79
São Paulo 70
Tokyo 66
Columbus 64
Dearborn 63
L’Aquila 62
Woodbridge 57
Helsinki 52
Orem 52
Milan 51
Nanchang 50
Lappeenranta 47
Shanghai 44
Brussels 41
Seattle 39
Frankfurt am Main 38
Assago 32
Brooklyn 32
Des Moines 32
Montreal 32
Houston 31
Stockholm 31
Chicago 30
Da Nang 30
Dong Ket 30
Johannesburg 30
Mountain View 30
Shenyang 30
Kunming 29
Phoenix 29
Warsaw 28
Rome 27
Manchester 26
Haiphong 25
Hebei 24
London 24
Mexico City 23
Pescara 23
San Francisco 23
Chennai 22
Denver 22
Tianjin 22
Jinan 21
Rio de Janeiro 21
Atlanta 20
Brno 20
Verona 20
Jiaxing 19
Kitzingen 19
Mumbai 19
New Delhi 19
Ankara 18
Cedar Knolls 17
Changsha 17
Falkenstein 17
Guangzhou 17
Jakarta 17
Pune 17
Toronto 17
Zhengzhou 17
Boston 14
Poplar 14
Turku 14
Belo Horizonte 13
Charlotte 13
Hangzhou 13
Philadelphia 13
Porto Alegre 13
Brasília 12
Ningbo 12
Norwalk 12
Totale 15.042
Salva come PNG Salva come JPEG
Nome #
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 181
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 175
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 160
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 159
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 158
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 157
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 156
Evaluating the multivisceral involvement on adult-onset Still’s disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study 154
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 153
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 151
Prognostic factors of adult onset Still’s disease: analysis of 100 cases in 3 tertiary referral centers 151
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 150
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 148
Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis 143
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 143
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 141
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. 138
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 138
Still's disease continuum from childhood to elderly: data from the international AIDA Network Still's disease registry 137
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 136
Cardiovascular disease in primary sjögren’s syndrome 136
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 136
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 135
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 133
Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 132
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 132
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences 131
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 130
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 130
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 128
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis 128
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 128
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 127
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 126
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 126
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 125
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 125
Stem cell therapies for systemic sclerosis 124
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 124
Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification 124
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 123
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 123
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 121
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 120
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 120
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 120
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 118
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 117
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 117
A comprehensive review on adult onset Still's disease 117
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 117
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 117
Parenchymal lung disease in adult onset Still's disease: An emergent marker of disease severity - Characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients 117
Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? 117
Diagnostic and interventional radiology fundamentals of synovial pathology 117
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment 117
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease 116
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms 116
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 116
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 115
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 114
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 114
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 114
Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases 113
T helper 1 response is correlated with widespread pain, fatigue, sleeping disorders and the quality of life in patients with fibromyalgia and is modulated by hyperbaric oxygen therapy 112
EFFICACY AND SAFETY OF RITUXIMAB TREATMENT IN EARLY PRIMARY SJOGREN'S SYNDROME: A CLINICAL, HISTOLOGICAL AND MOLECULAR STUDY 111
Interstitial lung disease in systemic sclerosis: current and future treatment. 111
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis 110
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 110
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al 110
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. 110
Long-term Safety of Rituximab in Primary Sjögren Syndrome: The Experience of a Single Center 109
Is minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren׳s syndrome? Association between clinical, histopathological, and molecular features: A retrospective study 109
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 109
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 109
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 109
The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational "real-life" study 108
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 108
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 108
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 107
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. 107
ASSESSING PRO-INFLAMMATORY PROPERTIES OF H-FERRITIN BY EX VIVO AND IN VITRO OBSERVATIONS 107
The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile 107
Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study. 106
The Vessels Contribute to Fibrosis in Systemic Sclerosis 106
Glucocorticoids in Rheumatoid Arthritis: The Silent Companion in the Therapeutic Strategy 106
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial 106
Computed Tomography and MR Imaging in Rheumatoid Arthritis 105
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 105
The Systemic Score May Identify Life‐Threatening Evolution in Still Disease: Data from the GIRRCS AOSD‐Study Group and the AIDA Network Still Disease Registry 103
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease 102
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 102
Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort 101
The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still’s disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles 100
Unfolding dermatologic spectrum of Behçet’s disease in Italy: real-life data from the International AIDA Network Behçet’s disease Registry 100
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 100
Laboratory assessment in patients with suspected rheumatic musculoskeletal diseases: challenges, pitfalls and perspectives 99
The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection 99
Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). 99
Anakinra effectiveness in refractory polyserositis: An Italian multicenter study 99
Totale 12.234
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202168 0 0 0 0 0 0 0 0 0 0 0 68
2021/2022803 39 24 153 63 17 12 31 42 66 44 61 251
2022/20233.501 226 193 60 362 209 328 49 217 1.676 21 119 41
2023/20241.043 117 46 69 99 76 325 31 54 22 59 41 104
2024/20254.770 118 79 404 213 624 449 575 308 1.120 222 344 314
2025/20269.223 507 918 823 992 887 562 1.572 368 894 1.023 549 128
Totale 22.759